Takeda Pharmaceutical Net Income 2010-2022 | TAK

Takeda Pharmaceutical annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Takeda Pharmaceutical net income for the quarter ending December 31, 2022 was $0.846B, a 66.37% increase year-over-year.
  • Takeda Pharmaceutical net income for the twelve months ending December 31, 2022 was $1.396B, a 69.59% decline year-over-year.
  • Takeda Pharmaceutical annual net income for 2022 was $2.048B, a 42.07% decline from 2021.
  • Takeda Pharmaceutical annual net income for 2021 was $3.534B, a 768.38% increase from 2020.
  • Takeda Pharmaceutical annual net income for 2020 was $0.407B, a 58.56% decline from 2019.
Takeda Pharmaceutical Annual Net Income
(Millions of US $)
2022 $2,048
2021 $3,534
2020 $407
2019 $982
2018 $1,682
2017 $1,069
2016 $665
2015 $-1,327
2014 $1,067
2013 $1,588
2012 $1,577
2011 $2,986
2010 $3,202
2009 $2,392
Takeda Pharmaceutical Quarterly Net Income
(Millions of US $)
2022-12-31 $846
2022-09-30 $445
2022-06-30 $809
2022-03-31 $-703
2021-12-31 $508
2021-09-30 $418
2021-06-30 $1,823
2021-03-31 $1,843
2020-12-31 $887
2020-09-30 $38
2020-06-30 $767
2020-03-31 $391
2019-12-31 $-296
2019-09-30 $501
2019-06-30 $-188
2018-12-31 $336
2018-06-30 $720
2017-06-30 $1,303
2016-06-30 $926
2015-06-30 $202
2015-03-31 $-1,892
2014-12-31 $156
2014-09-30 $260
2014-06-30 $326
2014-03-31 $-43
2013-12-31 $457
2013-09-30 $360
2013-06-30 $296
2013-03-31 $462
2012-12-31 $236
2012-09-30 $409
2012-06-30 $1,119
2012-03-31 $-460
2011-12-31 $322
2011-09-30 $775
2011-03-31 $394
2010-03-31 $426
2009-09-30 $-1
2009-03-31 $705
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $52.152B $31.791B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.788B 33.96
Catalent (CTLT) United States $12.158B 22.58
Stevanato Group S.p.A (STVN) Italy $6.916B 40.35
USANA Health Sciences (USNA) United States $1.206B 17.42
Taro Pharmaceutical Industries (TARO) Israel $0.907B 19.79
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.392B 2.22
Rafael Holdings (RFL) United States $0.040B 0.00
Lannett Co Inc (LCI) United States $0.018B 0.00